A J Scheen
Impact in
-
- Diabetes Treatment and Management
- Diabetes Management and Research
- Diabetes, Cardiovascular Risks, and Lipoproteins
Papers in
-
- Diabetes Treatment and Management 8
- Diabetes Management and Research 3
-
- Metabolism, Diabetes, and Cancer 3
- Peroxisome Proliferator-Activated Receptors 2
- Co-authors
- Philippe Lefèbvre (1 shared paper)Pierre Lefebvre (2 shared papers)Manuel J. Castillo (1 shared paper)Bernard Jandrain (2 shared papers)Delphine Magis (1 shared paper)Luc F. Van Gaal (3 shared papers)Nicolas Paquot (2 shared papers)Christine Kirkpatrick (1 shared paper)
- Journals
- Diabetes Care (1 paper)Cardiovascular Diabetology (1 paper)Annales d Endocrinologie (1 paper)PubMed (19 papers)
In The Last Decade
A J Scheen
21 papers receiving 333 citations
Peers
Comparison fields: 5 of 62
- Endocrinology, Diabetes and Metabolism 131
- Pharmacology 19
- Physiology 47
- Pharmacology 31
- Molecular Biology 127
Countries citing papers authored by A J Scheen
This map shows the geographic impact of A J Scheen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A J Scheen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A J Scheen more than expected).
Fields of papers citing papers by A J Scheen
This network shows the impact of papers produced by A J Scheen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A J Scheen. The network helps show where A J Scheen may publish in the future.
Co-authors
The 24 scholars most cited alongside A J Scheen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 22 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Thiazolidinediones and liver toxicity. | 2001 | 131 |
| 2 | Assessment of residual insulin secretion in diabetic patients using the intravenous glucagon stimulatory test: methodological aspects and clinical applications. | 1996 | 71 |
| 3 | 1999 | 69 | |
| 4 | [Alcohol, insulin sensitivity and diabetes]. | 2004 | 18 |
| 5 | [DREAM study: prevention of type 2 diabetes with ramipril and/or rosiglitazone in persons with dysglycaemia but no cardiovascular desease]. | 2006 | 10 |
| 6 | [Clinical study of the month. The CAPPP study: "The Captopril Prevention Project"]. | 1999 | 7 |
| 7 | [The cost of type 2 diabetes: summary of the Cost of Diabetes in Europe-Type II study (CODE-2) and analysis of the situation in Belgium]. | 2005 | 7 |
| 8 | [ADOPT study: which first-line glucose-lowering oral medication in type 2 diabetes?]. | 2007 | 6 |
| 9 | [How I explore ... the risk of a patient developing type 2 diabetes]. | 2002 | 4 |
| 10 | [Management of gestational diabetes]. | 2013 | 4 |
| 11 | [The IDEAL study comparing simvastatin 20-40 mg versus atorvastatin 80 mg for secondary prevention after myocardial infarction: between two ideas of the ideal]. | 2006 | 4 |
| 12 | [Glucotoxicity and lipotoxicity, two implicated accomplices in the vicious circle of type 2 diabetes]. | 1999 | 3 |
| 13 | 2022 | 2 | |
| 14 | [Medication of the month. Glucovance in type 2 diabetes, a fixed combination of metformin-glibenclamide for the treatment of a bipolar metabolic disease]. | 2003 | 2 |
| 15 | [Similar reduction in new cases of type 2 diabetes with angiotensin receptor blocker and ACE inhibitor: comparison of meta-analyses of prospective randomised trials]. | 2005 | 2 |
| 16 | [Initiave to promote quality of care and epidemiology of diabetes mellitus]. | 2005 | 2 |
| 17 | [Adiponectin: a new adipocytokine]. | 2003 | 2 |
| 18 | [Linagliptin (Trajenta): a selective DPP-4 inhibitor with limited renal elimination]. | 2012 | 2 |
| 19 | [Sitagliptin in the treatment of type 2 diabetes: insights five years after commercialisation]. | 2013 | 1 |
| 20 | [Effects of glimepiride (Amarylle) in type 2 diabetic patients: results of the Belgian study RECORD in general medicine]. | 2006 | 1 |
About A J Scheen
A J Scheen is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology, Pharmacology, Physiology and Surgery, having authored 22 papers that have together received 349 indexed citations. Recurring topics across this work include Diabetes Treatment and Management (8 papers), Pharmacology and Obesity Treatment (4 papers), Diabetes Management and Research (3 papers), Metabolism, Diabetes, and Cancer (3 papers), Peroxisome Proliferator-Activated Receptors (2 papers), Healthcare Systems and Practices (2 papers), Clinical practice guidelines implementation (2 papers) and Diet and metabolism studies (2 papers). The work is most often cited by research in Endocrinology, Diabetes and Metabolism (131 citations), Pharmacology (19 citations), Physiology (47 citations), Pharmacology (31 citations) and Molecular Biology (127 citations). A J Scheen has collaborated with scholars based in Belgium and France. Frequent co-authors include Philippe Lefèbvre, Pierre Lefebvre, Manuel J. Castillo, Bernard Jandrain, Delphine Magis, Luc F. Van Gaal, Nicolas Paquot, Christine Kirkpatrick, Patrick Emonts and Régis Radermecker. Their work appears in journals such as Diabetes Care, Cardiovascular Diabetology, Annales d Endocrinologie and PubMed.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.